Professional Bio:

Nishant Shah, MD is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. He has conducted research in cardiovascular disease prevention, particularly in the space of dyslipidemias. He is currently a member of the Duke Cardiometabolic Prevention Clinic and is the lead for the Duke Health System Remote Lipid Monitoring Program. He also serves as the clinical lead in the implementation of Inclisiran across Duke Health System. Dr. Shah also holds many clinical, educational and national roles. Clinically, he rounds on the inpatient cardiology service as well as the cardiac intensive care unit. With his imaging background he also reads echocardiograms at Duke. Additionally, he has a cardiometabolic prevention clinic where he sees patients with complex dyslipidemias, resistant hypertension, obesity, and many other complex cardiovascular disorders. Nationally, Dr. Shah is the co-char for the American College of Cardiology Cardiometabolic Prevention working group, chair of the early career and fellow in training work group for the American Society of Preventive Cardiology, and member of the American Heart Association Outpatient Advisory Committee. Throughout his time at Duke he has won many teaching awards including the Thomas M. Bashore Fellows Teaching Award and Department of Medicine Cardiology Educator of the year award. He also serves as the associate program director of the cardiovascular medicine fellowship program. Additionally, he is a board member for the North Carolina Chapter of the American College of Cardiology From the research standpoint Dr. Shah holds grants for the CVMOBIUS2 study where he serves as the DCRI PI for a study that evaluates the effectiveness of PCSK9 inhibitors in the Prevention of Cardiovascular Disease in a real-world context. He also holds a grant for a cross sectional study of lipoprotein (a) in patients with documented atherosclerotic cardiovascular disease. Furthermore, he is a member of the Cardiohealth Alliance executive committee and is a co-investor in studies evaluating ways to improve care in patients with elevated Lp(a). Dr. Shah also is a site PI for several advanced lipid therapeutic cardiovascular outcomes clinical trials. Dr. Shah graduated from North Carolina State University and completed medical school at Wake Forest University School of Medicine. He completed his internal medicine residency at the Johns Hopkins Hospital and then his cardiovascular fellowship at the Cleveland Clinic. He joined the faculty at Duke in 2019 and DCRI in 2020.